Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Viyash Scientific ( (IN:VIYASH) ).
Viyash Scientific Limited has reshaped its board by appointing Amit Jain and Abhiroop Jayanthi, both representatives of the Carlyle group, as additional non-executive, non-independent directors, subject to shareholder approval. The move underscores Carlyle’s influence in the company’s governance and may signal a stronger private equity-backed strategic direction.
The board also approved a revision to the company’s Employee Stock Option Scheme 2026, trimming the option pool from 13,475,000 to 13,098,000 stock options while retaining other terms. The recalibrated ESOP pool reflects a more measured equity incentive structure, balancing employee alignment with shareholder dilution concerns as the company refines its long-term compensation strategy.
More about Viyash Scientific
Viyash Scientific Limited, formerly known as Sequent Scientific, operates in the scientific and pharmaceutical sector, with its registered office in Hyderabad, India. The company is listed on BSE and NSE, indicating a public market presence and a focus on regulated, exchange-listed operations.
Average Trading Volume: 34,439
Technical Sentiment Signal: Strong Buy
Current Market Cap: 90.47B INR
For a thorough assessment of VIYASH stock, go to TipRanks’ Stock Analysis page.